However, the question of whether PD‐1/PD‐L1 inhibitors hold efficacy for PD‐L1 low expression (CPS < 1 or TPS < 1%) patients has remained unanswered, a query that has garnered heightened attention in other malignancies such as melanoma, renal cell carcinoma, non‐small cell lung cancer (NSCLC), and esophageal carcinomas.19, 20. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.